Arcutis Biotherapeutics ARQT
NASDAQ ARQT
$27.17 +0.97 (+3.70%)
As of: Nov 10, 2026 · 2:32 PM EST

Arcutis Biotherapeutics (ARQT) EV to EBIT (2026)

Updated

Arcutis Biotherapeutics' (ARQT) EV to EBIT came in at 90.17 for Q2 2026, down 89.5% from the prior quarter.

Analysis

Arcutis Biotherapeutics (ARQT) EV to EBIT (2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EV to EBIT at Arcutis Biotherapeutics was 75.24.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Arcutis Biotherapeutics 3.53 Bn 2.65 Bn 131.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 87.34
Jun 30, 2026 90.17
Mar 31, 2026 858.00
API Access

Arcutis Biotherapeutics EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=ARQT&period=max&api_key=YOUR_API_KEY